{"entity":{"id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","aka":[],"tldr":"A phase 1/2 trial of Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Synthekine, now recruiting.","summary":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers is a phase 1/2 interventional study registered as NCT05098132 by Synthekine, with 364 participants planned, started 2022-01-25 and due to reach its primary completion in 2029-01. Interventions recorded: STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin. Conditions listed: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05098132","url":"https://clinicaltrials.gov/study/NCT05098132"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pemetrexed","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05098132","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications","sponsor":"Synthekine","enrolled":364,"outcomes":[]},"route":"/trials/nct05098132/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}]}}